Celcuity CELC 深 沪
等待开盘 11-05 09:30:00 美东时间
73.565
-1.625
-2.16%
华盛通- 最 高75.435
- 今 开72.83
- 成交量 33.42万股
- 最 低 72.56
- 昨 收 75.19
- 总市值 31.21亿
- 52周最高 83.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.575
- 委 比 51.56%
- 总股本 4242.67万
- 历史最高 83.00
- 量 比 0.66
- 振 幅 3.82%
- 历史最低 4.03
- 每 手 1
- 风险率 19.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotech company focused on targeted therapies for oncology, announced its participation in the Stifel 2025 Healthcare Conference in New York on November 11-13, 2025. CEO Brian Sullivan will attend a fireside chat at 10:00 a.m. ET on November 11. Celcuity is developing gedatolisib, a pan-PI3K and mTORC1/2 inhibitor targeting the PI3K/AKT/mTOR pathway. The company has ongoing Phase 3 clinical trials, V...
11-04 12:05
美股周涨跌榜 | 卡朋特科技周涨32%，Q3净利润1.23亿美元； SanDisk Corp周涨32.8%创历史新高
卡朋特科技周涨32%，Q3净利润1.23亿美元，同比增加45.22%； 存储芯片遇“超级周期”，SanDisk Corp周涨32.8%创历史新高>>
10-25 10:05
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
美股牛股 | 广船国际技术暴涨155%！芯片重大突破引爆市场；“人造肉”公司BYND大涨超127%
广船国际技术暴涨逾155%！AI芯片性能媲美主流图形处理器；“人造肉”公司BYND大涨超127%，将近11.5亿美元零息可转换债券置换成新的资产组合>>
10-21 14:37
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Replimune Group (NASDAQ:REPL) stock increased by 95.3% to $8.79 during...
10-20 20:08
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
Celcuity Inc. announced updated results from a Phase 1 trial evaluating gedatolisib combined with Nubeqa in men with mCRPC. The six-month radiographic progression-free survival (rPFS) rate was 67% with a median rPFS of 9.1 months. Both doses of gedatolisib were generally well-tolerated, with no treatment-related adverse events leading to discontinuation. Celcuity plans to expand the trial to determine the recommended Phase 2 dose.
10-18 08:30
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
Celcuity Inc. announced the full enrollment of the PIK3CA mutant cohort in their Phase 3 VIKTORIA-1 clinical trial and provided updated analysis from a Phase 1b trial. The Phase 1b trial showed a median progression-free survival (PFS) of 14.6 months for HR+/HER2-/PIK3CA-mutated advanced breast cancer patients treated with gedatolisib, fulvestrant, and palbociclib. The Phase 3 trial expects to report topline data in late Q1 or early Q2 2026.
10-18 08:30
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
USA News Group News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- USA News Group News Commentary – Major pharmaceutical companies are unveilin...
10-07 21:00
美股大行评级 | 潜在涨幅1176.6%！Ascendiant Capital上调Society Pass目标价至18美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从15美元升至18美元；Ascendiant Capital：维持Surgepays"买入"评级，目标价从9美元升至9.5美元
10-06 08:35
Needham Reiterates Buy on Celcuity, Maintains $70 Price Target
Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.
10-03 18:38
